Written by LAURAN NEERGAARD
Pfizer said Wednesday that a booster dose of its COVID-19 vaccine may offer important protection against the new omicron variant even though the initial two doses appear significantly less effective.
Pfizer and its partner BioNTech said that while two doses may not be protective enough to prevent infection, lab tests showed a booster increased by 25-fold people’s levels of virus-fighting antibodies against the omicron variant.
Blood samples taken a month after a booster showed people harbored levels of omicron-neutralizing antibodies that were similar to amounts proven protective against earlier variants after two doses.
Scientists don’t yet know how big a threat the omicron variant really is. Currently the extra-contagious delta variant is responsible for most of the COVID-19 cases in the U.S. and other countries.
But the omicron variant, discovered late last month, carries an unusually large number of mutations and scientists are racing to learn how easily it spreads, whether it causes illness that is more serious or milder than other coronavirus types — and how much it might evade the protection of prior vaccinations.
Pfizer’s findings, announced in a press release, are preliminary and haven’t yet undergone scientific review. But they’re the first from a vaccine maker examining whether the booster doses that health authorities are urging people to get may indeed make an important difference.
Scientists have speculated that the high jump in antibodies that comes with a third dose of COVID-19 vaccines might be enough to counter any decrease in effectiveness.
Pfizer and BioNTech already are working to create an omicron-specific vaccine in case it’s needed.
Antibody levels predict how well a vaccine may prevent infection with the coronavirus but they are just one layer of the immune system’s defenses. Pfizer said two doses of the vaccine should still protect against severe disease, because the mutations in omicron don’t appear to hamper one of those other defenses, T cells that fight the virus after infection sets in.
“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is maximized with a third dose of our vaccine,” Pfizer CEO Albert Bourla said in a statement.
Pfizer’s announcement had an immediate impact on U.S. markets. Futures that had pointed to a lower open reversed course in seconds and swung solidly to the positive with the Dow jumping almost 200 points.
Photo via AP Photo/Steven Senne.
Related Stories
‹

Pfizer Seeking Emergency Use of Its COVID-19 Vaccine in U.S.Pfizer said Friday it is asking U.S. regulators to allow emergency use of its COVID-19 vaccine, starting the clock on a process that could bring limited first shots as early as next month and eventually an end to the pandemic — but not until after a long, hard winter. The action comes days after Pfizer […]

Moderna Says Its Low-Dose COVID Shots Work for Kids Under 6Written by LAURAN NEERGAARD Moderna’s COVID-19 vaccine works in babies, toddlers and preschoolers, the company announced Wednesday — and if regulators agree it could mean a chance to finally start vaccinating the littlest kids by summer. Moderna said in the coming weeks it would ask regulators in the U.S. and Europe to authorize two small-dose […]

Pfizer: COVID-19 Shot 95% Effective, Seeking Clearance SoonPfizer said Wednesday that new test results show its coronavirus vaccine is 95% effective, is safe and also protects older people most at risk of dying — last data needed to seek emergency use of limited shot supplies even as the catastrophic outbreak worsens across the globe. The announcement from Pfizer and its German partner […]

Pfizer Says COVID-19 Vaccine Is Looking 90% EffectivePfizer said Monday that an early peek at the data on its coronavirus vaccine suggests the shots may be a robust 90% effective at preventing COVID-19, putting the company on track to apply later this month for emergency-use approval from the Food and Drug Administration. The announcement, less than a week after a presidential election […]

'We Need Your Help': Participants Needed for UNC's COVID-19 Vaccine TrialsClinical researchers in the UNC Division of Infectious Diseases are asking the community to partake in a large phase 3 clinical trial for a COVID-19 vaccine. Sites across the country, including one at UNC, are testing the mRNA-1273 vaccine developed by Moderna in a large-scale study aiming for 30,000 participants. The potential Moderna vaccine is […]

Moderna Sues Pfizer Over Patents Behind COVID-19 VaccineWritten by TOM MURPHY COVID-19 vaccine maker Moderna is suing Pfizer and the German drugmaker BioNTech, accusing its main competitors of copying Moderna’s technology in order to make their own vaccine. Moderna said Friday that Pfizer and BioNTech’s vaccine Comirnaty infringes on patents Moderna filed several years ago protecting the technology behind its preventive shot, […]

Moderna Seeks To Be 1st With COVID Shots for Littlest KidsModerna on Thursday asked U.S. regulators to authorize low doses of its COVID-19 vaccine for children younger than 6, a long-awaited move toward potentially opening shots for millions of tots by summer.
![]()
Moderna Seeks FDA Authorization for 4th Dose of COVID ShotWritten by ZEKE MILLER Drugmaker Moderna asked the Food and Drug Administration on Thursday to authorize a fourth shot of its COVID-19 vaccine as a booster dose for all adults. The request is broader than rival pharmaceutical company Pfizer’s request earlier this week for the regulator to approve a booster shot for all seniors. In […]

Moderna: Initial Booster Data Shows Good Results on OmicronWritten by THE ASSOCIATED PRESS Moderna said Monday that a booster dose of its COVID-19 vaccine should offer protection against the rapidly spreading omicron variant. Moderna said lab tests showed the half-dose booster shot increased by 37 times the level of so-called neutralizing antibodies able to fight omicron. And a full-dose booster was even stronger, […]

Pfizer Says COVID Booster Offers Protection Against OmicronWritten by LAURAN NEERGAARD Pfizer said Wednesday that a booster dose of its COVID-19 vaccine may offer important protection against the new omicron variant even though the initial two doses appear significantly less effective. Pfizer and its partner BioNTech said that while two doses may not be protective enough to prevent infection, lab tests showed a booster […]
›